%0 Case Reports
%T Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature.
%A Xu G
%A Yang M
%A Qian W
%J Int J Clin Exp Med
%V 8
%N 10
%D 2015
%M 26770625
暂无%R 
%X Multiple myeloma (MM) accounts for 1.5% of all cancers and approximately 13% of all hematologic malignancies. Therapy for MM has substantially improved after the application of immunomodulatory drugs and proteasome inhibitors. The first proteasome inhibitor, bortezomib, can be considered a major milestone in treatment of MM, greatly improving the response rates and overall survival in front-line and relapsed/refractory settings. However, the prognosis of patients with progressive disease remains poor. In this article, we report a case of refractory MM patient who gained a long time disease control by bortezomib mono-therapy and do a critical review of the literature. We aim to share our experience of efficiency and safety of the long term mono-therapy of bortezomib in a refractory MM.